Sep
28
2021
Upcoming webinar

GMP manufacturing for exosome-based therapies: the critical role of analytics and process design for clinical production and scale-up

Tuesday 28th September 2021 08:00 PDT; 11:00 EDT; 16:00 BST; 17:00 CEST

When producing exosomes-based therapies, analytics and process design are key to build a successful manufacturing process that keeps you in control of your product for clinical and beyond. There is a fine balance to find, in order to measure appropriately the critical quality attributes of your product, without over-complicating an already complex validation process. During this webinar, our experts will propose a roadmap for EV analytics and process design.

  • Extracellular vesicle biology as new drug modality
  • Analytics for process design and definition of exosome drug substance
  • Manufacturing of exosomes, challenges and opportunities
  • How to establish an effective process for clinical manufacturing and beyond

Marcos Langtry

Head of Allogeneic Cell Therapy Commercial Development, Lonza Pharma & Biotech

Marcos Langtry is Head of Allogeneic Cell Therapy Commercial Development at Lonza Pharma & Biotech. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos held several senior level positions at TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he acquired extensive experience with aseptically filled, biologic and cell therapy products.

Marcos Langtry holds a Master´s degree in Biochemical Engineering from University College London (UK) and an MBA from Imperial College London (UK). He is also qualified as Chartered Engineer (CEng) and Chartered Scientist (CSci).

Davide Zocco

Research & Development Senior Manager, Lonza Pharma & Biotech

Davide Zocco has joined Lonza (2020) as senior manager to lead R&D projects for the manufacturing of extracellular vesicles (VEs) within Cell and Gene Therapy Business Unit. He holds the position of Chief Technology Officer at his former company, Exosomics, a Lonza’s strategic R&D partner, to foster the development of protocols and kits for the isolation and characterization of EVs from body fluids. He is author of peer-reviewed publications in high profile journals, including Nature Chemical Biology, PNAS and American Journal of Pathology (>2000 citations), and of three patents in the extracellular vesicle field. He holds a PhD from University College Dublin (Ireland) and he was a postdoctoral research fellow at Harvard Medical School (USA).

0
Days
1
Hrs
20
Min

SPEAKERS

Marcos Langtry
Head of Allogeneic Cell Therapy Commercial Development, Lonza Pharma & Biotech
Marcos Langtry
Head of Allogeneic Cell Therapy Commercial Development, Lonza Pharma & Biotech

Marcos Langtry is Head of Allogeneic Cell Therapy Commercial Development at Lonza Pharma & Biotech. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos held several senior level positions at TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he acquired extensive experience with aseptically filled, biologic and cell therapy products.

Marcos Langtry holds a Master´s degree in Biochemical Engineering from University College London (UK) and an MBA from Imperial College London (UK). He is also qualified as Chartered Engineer (CEng) and Chartered Scientist (CSci).

Davide Zocco
Research & Development Senior Manager, Lonza Pharma & Biotech
Davide Zocco
Research & Development Senior Manager, Lonza Pharma & Biotech
Davide Zocco has joined Lonza (2020) as senior manager to lead R&D projects for the manufacturing of extracellular vesicles (VEs) within Cell and Gene Therapy Business Unit. He holds the position of Chief Technology Officer at his former company, Exosomics, a Lonza’s strategic R&D partner, to foster the development of protocols and kits for the isolation and characterization of EVs from body fluids. He is author of peer-reviewed publications in high profile journals, including Nature Chemical Biology, PNAS and American Journal of Pathology (>2000 citations), and of three patents in the extracellular vesicle field. He holds a PhD from University College Dublin (Ireland) and he was a postdoctoral research fellow at Harvard Medical School (USA).